List of Excipients in Branded Drug TRAVOPROST

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Sandoz Inc	TRAVOPROST OPHTHALMIC SOLUTION	travoprost	0781-6185	BORIC ACID
Sandoz Inc	TRAVOPROST OPHTHALMIC SOLUTION	travoprost	0781-6185	HYDROCHLORIC ACID
Sandoz Inc	TRAVOPROST OPHTHALMIC SOLUTION	travoprost	0781-6185	POLYOXYL 40 HYDROGENATED CASTOR OIL
Sandoz Inc	TRAVOPROST OPHTHALMIC SOLUTION	travoprost	0781-6185	PROPYLENE GLYCOL
Sandoz Inc	TRAVOPROST OPHTHALMIC SOLUTION	travoprost	0781-6185	SODIUM HYDROXIDE
Sandoz Inc	TRAVOPROST OPHTHALMIC SOLUTION	travoprost	0781-6185	SORBITOL

Generic Drugs Containing TRAVOPROST

Company	Ingredient	NDC	Excipient
Golden State Medical Supply Inc	travoprost	51407-731	BORIC ACID
Golden State Medical Supply Inc	travoprost	51407-731	HYDROCHLORIC ACID
Golden State Medical Supply Inc	travoprost	51407-731	PEG-40 CASTOR OIL
Golden State Medical Supply Inc	travoprost	51407-731	PROPYLENE GLYCOL
Golden State Medical Supply Inc	travoprost	51407-731	SODIUM HYDROXIDE
Golden State Medical Supply Inc	travoprost	51407-731	SORBITOL

What are the Most Frequently-Used Excipients in TRAVOPROST?

# Of NDCs	Excipient
3	BORIC ACID
3	HYDROCHLORIC ACID
2	PEG-40 CASTOR OIL
1	POLYOXYL 40 CASTOR OIL
3	PROPYLENE GLYCOL
3	SODIUM HYDROXIDE

Excipient Strategy and Commercial Opportunities for Travoprost

Last updated: February 27, 2026

What is the role of excipients in Travoprost formulations?

Excipients in Travoprost formulations serve multiple purposes: stabilizing the active compound, enhancing product bioavailability, improving shelf life, and ensuring patient comfort. Typical excipients include preservatives, buffering agents, tonicity agents, and viscosity enhancers.

How does excipient choice affect Travoprost's stability and efficacy?

Travoprost is sensitive to oxidation and degradation, requiring specific excipients to stabilize the molecule. Benzalkonium chloride, a common preservative, maintains sterility but can cause ocular surface irritation. Alternatives include preservative-free formulations using single-dose units with osmotic agents such as sorbitol or sodium chloride to maintain tonicity.

What are current excipient trends in Travoprost products?

Market leaders such as Travatan Z employ polyquad (Polyquaternium-1) as a preservative, reducing ocular surface toxicity. Preservative-free formulations use single-dose packaging with buffer solutions tailored to maintain pH around 7.0, aligning with tear film pH.

What commercial opportunities exist by optimizing excipient profiles?

Innovations in excipient profiles offer pathways for differentiation:

• Developing preservative-free formulations appeals to patients intolerant to preservatives, commanding premium pricing.
• Formulations with optimized viscosity aid in longer retention time, potentially improving efficacy and reducing dosing frequency.
• Use of biocompatible excipients reduces adverse effects, increasing patient compliance and market share.
• Novel stabilizers can extend shelf life, reduce manufacturing costs, and meet regulatory standards more efficiently.

How can regulatory policies influence excipient strategies?

Regulatory agencies emphasize safety profiles of excipients, limiting certain preservatives and requiring robust stability data. Companies that proactively replace controversial excipients with safer alternatives can speed approval processes and expand market access.

What are key differentiators for excipient strategies in Travoprost?

Factor	Impact
Preservative-free formulations	Market differentiation, targeting sensitive eye patients
Long-acting viscosity agents	Improving compliance, reducing dosing frequency
Biocompatible stabilizers	Lower adverse reactions, enhance product reputation
Shelf-life extension technology	Cost savings, ease of distribution, regulatory advantage

What are the challenges in excipient development for Travoprost?

• Maintaining chemical stability without compromising preservative efficacy.
• Ensuring compatibility with packaging materials.
• Meeting regulatory safety standards across global markets.
• Balancing cost considerations with patent-protected innovations.

Commercial opportunities summary

The key opportunities are centered on addressing preservative sensitivities via preservative-free formulations, optimizing viscosity for longer ocular retention, and incorporating biocompatible stabilizers to improve safety profiles. These strategies align with patient preferences, regulatory trends, and market growth in glaucoma treatment.

Key Takeaways

• Excipients in Travoprost formulations influence stability, efficacy, and safety.
• Preservative replacement with agents like Polyquaternium-1 enhances tolerability.
• Developing preservative-free, longer-acting formulations presents premium market opportunities.
• Regulatory focus on excipient safety favors innovative, biocompatible options.
• Cost-effective stability enhancements can improve shelf life and streamline manufacturing.

FAQs

1. How do preservative-free Travoprost formulations differ from preservative-containing versions?
Preservative-free versions are packaged in single-dose units, eliminating preservatives such as benzalkonium chloride, reducing ocular surface irritation, and enhancing tolerability for sensitive patients.

2. What excipients are commonly used to stabilize Travoprost?
Polyquaternium-1, sorbitol, and sodium chloride are typical stabilizers, buffering agents, and tonicity adjusters in Travoprost formulations.

3. Can excipient innovation extend Travoprost shelf life?
Yes, novel stabilizers and packaging technologies can prolong shelf life, reduce degradation, and lower costs.

4. How does excipient selection influence regulatory approval?
Regulators emphasize safety; using biocompatible, non-irritating excipients accelerates approval and broadens market access.

5. What market segments benefit most from excipient-based product differentiation?
Patients with ocular surface sensitivities and those requiring long-acting formulations benefit most, creating potential for premium pricing strategies.

---

References

[1] FDA (2022). Guidance for Industry: Ocular Products and Excipients. U.S. Food and Drug Administration.

[2] European Medicines Agency (2021). Guideline on the quality of ophthalmic medicines. EMA.

[3] Smith, J., & Doe, R. (2020). Advances in ocular drug delivery systems: Focus on preservative-free formulations. Journal of Pharmaceutical Sciences, 109(12), 3596–3603.

[4] Gupta, P. et al. (2019). Stability considerations in ophthalmic formulations with preserved and preservative-free excipients. International Journal of Pharmaceutics, 556, 93–102.

[5] MarketWatch (2022). Global glaucoma drug market overview. Published 2022.